Información del producto
- (20S)-Propanaxadiol
- (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(10R,12S,13R,14R,17S)-12-hydroxy-17-[(2R)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,10,13,14-pentamethyl-2,3,5,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxa
- (3Beta,12Beta)-12,20-Dihydroxydammar-24-En-3-Yl 2-O-Beta-D-Glucopyranosyl-Beta-D-Glucopyranoside
- (3β,12β,20R)-12,20-Dihydroxydammar-24-en-3-yl 2-O-β-<span class="text-smallcaps">D</smallcap>-glucopyranosyl-β-<smallcap>D</span>-glucopyranoside
- (3β,12β,20R)-12,20-Dihydroxydammar-24-en-3-yl O-β-<span class="text-smallcaps">D</smallcap>-glucopyranosyl-(1→2)-β-<smallcap>D</span>-glucopyranoside
- (5xi,8xi,9xi,12alpha,14beta,20R)-12,20-dihydroxylanost-24-en-3-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside
- (8xi,9xi,12alpha,14beta,17alpha)-12-hydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,10,14-tetramethylgonan-3-yl 2-O-[3-deoxy-3-(hydroxymethyl)-beta-D-glucopyranosyl]-beta-D-glucopyranoside
- 20(R)-Ginsenoside Rg<sub>3</sub>
- 20(R)-Propanaxadiol
- 20(S)-Ginsenoside-Rg3
- Ver más sinónimos
- 20R-Ginsenoside Rg3
- Beta-D-Glucopyranoside,(3-Beta,12-Beta)-12,20-Dihydroxydammar-24-En-3-Yl2-O-B
- Dammar-24-Ene-12-Beta,20-Diol,3-Beta-((2-O-Beta-D-Glucopyranosyl-Beta-D-Gluc
- Dammar-24-ene-12β,20-diol, 3β-[(2-O-β-D-
- Eta-D-Glucopyranosyl-
- Ginsenoside rg3(R)
- Opyransoyl)Oxy)-
- R-Ginsenoside Rg<sub>3</sub>
- beta-D-Glucopyranoside,(3beta,12beta)-12,20-dihydroxydammar-24-en-3-yl 2-O-beta-D-glucopyranosyl
- β-<span class="text-smallcaps">D</smallcap>-Glucopyranoside, (3β,12β,20R)-12,20-dihydroxydammar-24-en-3-yl 2-O-β-<smallcap>D</span>-glucopyranosyl-
- (3β,12β,20R)-12,20-Dihydroxydammar-24-en-3-yl 2-O-β-D-glucopyranosyl-β-D-glucopyranoside
- (3β,12β,20R)-12,20-Dihydroxydammar-24-en-3-yl O-β-D-glucopyranosyl-(1→2)-β-D-glucopyranoside
- β-D-Glucopyranoside, (3β,12β,20R)-12,20-dihydroxydammar-24-en-3-yl 2-O-β-D-glucopyranosyl-
20(R)-Ginsenoside Rg3 has shown multiple pharmacological activities and been considered as one of the most promising approaches for fatigue treatment, however, 20(R)-Ginsenoside Rg3 has a low bioavailability after oral administration in human, so, 20(R)-Rg3 can be by intranasal administration, the mechanism was related to the increase of the storage of hepatic glycogen, and the decrease of the accumulation of metabolite such as lactic acid and serum urea nitrogen.
Propiedades químicas
Consulta técnica sobre: BP-BP0040 20(R)-Ginsenoside Rg3
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.